SCHEMBL20135508

SCHEMBL20135508

CCC1(c2ccc(C(=O)N3CCC(c4nnc(-c5ccc(C)cc5C)o4)CC3)cc2)NC(=O)NC1=O

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.50
ADAM17 P78536 1/20 0.39
ADAMTS5 Q9UNA0 3/20 0.38
FASN P49327 4/20 0.36
TNKS O95271 2/20 0.35
PARP1 P09874 2/20 0.35
PARP2 Q9UGN5 2/20 0.35
PRKAB2 O43741 1/20 0.35
PRKAG1 P54619 1/20 0.35
PRKAA2 P54646 1/20 0.35
PRKAA1 Q13131 1/20 0.35
PRKAG3 Q9UGI9 1/20 0.35
PRKAG2 Q9UGJ0 1/20 0.35
PRKAB1 Q9Y478 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
CRBN Q96SW2 1/20 0.35
LMNA P02545 1/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29688756 1.00 TP53 (0.50) TP53ADAM17ADAMTS5FASNTNKS
SCHEMBL20135505 1.00 TP53 (0.50) TP53ADAM17ADAMTS5FASNTNKS
SCHEMBL20135702 0.91 TP53 (0.53) TP53ADAM17ADAMTS5FASNTNKS
SCHEMBL20135700 0.91 TP53 (0.53) TP53ADAM17ADAMTS5FASNTNKS
SCHEMBL20134871 0.89 TP53 (0.53) TP53ADAM17ADAMTS5FASNTNKS
SCHEMBL29688759 0.89 TP53 (0.53) TP53ADAM17ADAMTS5FASNTNKS
SCHEMBL20134873 0.89 TP53 (0.53) TP53ADAM17ADAMTS5FASNTNKS
SCHEMBL20135487 0.83 TP53 (0.53) TP53ADAM17ADAMTS5TNKSPARP1
SCHEMBL29688929 0.79 ADAM17 (0.41) ADAM17ADAMTS5MEN1KMT2ACRBN
SCHEMBL20135049 0.79 ADAM17 (0.41) ADAM17ADAMTS5MEN1KMT2ACRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 TP53 4082/4885ADAM17 36/4885ADAMTS5 23/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 TP53 3806/4885ADAM17 39/4885ADAMTS5 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.